Bevacizumab biosimilar - Alphamab/R-Pharm

Drug Profile

Bevacizumab biosimilar - Alphamab/R-Pharm

Alternative Names: Avastin biosimilar - Alphamab/R-Pharm; RPH 001

Latest Information Update: 15 May 2015

Price : $50

At a glance

  • Originator Alphamab; R-Pharm
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase I Cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 May 2015 R-Pharm announces intention to submit MAA in Russia and Turkey in 2015
  • 08 May 2015 Bevacizumab biosimilar is available for licensing (https://mybio.org/exhibitor/member/118060)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top